PDCD1 and Hodgkins lymphoma: Several studies, in patients with chemorefractory RR-HL, have documented that treatment with anti-PD1, likely due to a clonal ‘reshaping’ effect, enhance/restores sensitivity to anticancer agents, including those present in the conditioning regimens for ASCT [32,33,34].